华东医药（000963）公告，2024年营业收入419.06亿元，同比增长3.16%。归属于上市公司股东的净利 润35.12亿元，同比增长23.72%。基本每股收益2元/股，同比增长23.60%。公司拟向全体股东每10股派 发现金红利5.8元(含税)，送红股0股(含税)，不以公积金转增股本。 ...

据了解，中证浙江企业综合指数与中证浙江民营企业指数分别选取注册地在浙江省的全部上市公司证券 与民营上市公司证券作为指数样本，以反映浙江省上市公司证券和民营上市公司证券的整体表现。该指 数以2004年12月31日为基日，以1000.0点为基点。 金融界4月14日消息，上证指数高开高走，中证浙江民营企业指数 (浙江民企，000840)报7165.72点。 数据统计显示，中证浙江民营企业指数近一个月下跌12.68%，近三个月上涨3.32%，年至今下跌 1.28%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。特殊情况下将对指数进行临时调整。当样本退市时，将其从指数样本中剔除。样本公司发生收 购、合并、分拆等情形的处理，参照计算与维护细则处理。 从指数持仓来看，中证浙江民营企业指数十大权重分别为：同花顺（2.27%）、三花智控（2.22%）、 华友钴业（1.69%）、恒生电子（1.58%）、拓普集团（1.32%）、华东医药（1.31%）、新和成 （1.3%）、大华股份（1.23%）、中控技术（1.22%）、卫星化学（1.15%）。 从中证浙江民营企业指数持仓样 ...

Group 1 - The Shanghai Composite Index opened high and the CSI 300 Pharmaceutical and Biotechnology Index reported 7370.94 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has decreased by 1.33% in the past month, increased by 5.20% in the past three months, and decreased by 0.98% year-to-date [1] - The CSI 300 Index is categorized into 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] Group 2 - The top ten weights in the CSI 300 Pharmaceutical and Biotechnology Index are: Heng Rui Medicine (24.17%), WuXi AppTec (14.58%), Pian Zai Huang (6.92%), Yunnan Baiyao (5.68%), Kelun Pharmaceutical (5.11%), East China Pharmaceutical (3.63%), New Hope Liuhe (3.58%), Shanghai Raas (3.57%), Changchun High-tech (3.53%), and Fosun Pharma (3.39%) [1] - The market share of the CSI 300 Pharmaceutical and Biotechnology Index is 61.98% from the Shanghai Stock Exchange and 38.02% from the Shenzhen Stock Exchange [2] - The industry composition of the index includes: chemical drugs (42.08%), traditional Chinese medicine (20.00%), pharmaceutical and biotechnology services (19.84%), and biological drugs (18.08%) [2] Group 3 - The index samples are adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made when the CSI 300 Index samples are modified [2] - Special events affecting sample companies may lead to adjustments in the industry classification of the CSI 300 Industry Index [2]

Group 1: Policy Support for Pharmaceutical Innovation - Beijing encourages local production of innovative pharmaceuticals, supporting enterprises in importing significant drug and medical device varieties, and promoting the industrialization and large-scale application of innovative products [1] - Shenzhen offers financial incentives for innovative drugs that complete clinical trials and achieve domestic and international market entry, with rewards up to 30 million yuan based on clinical trial phases [2] Group 2: Company Developments - Heng Rui Medicine grants exclusive commercialization rights of its new drug SHR7280 to Germany's Merck, receiving an upfront payment of 15 million euros and potential milestone payments and sales royalties [3] - East China Pharmaceutical's subsidiary receives approval for clinical trials of DR30206, a novel antibody fusion protein targeting PD-L1, VEGF, and TGF-β, marking a significant advancement in its development [4] Group 3: Market Trends and Opportunities - Blood product stocks, including Wei Guang Bio and Pai Lin Bio, experience a surge due to the rigid demand for blood products and potential price increases from U.S. tariffs, benefiting domestic companies and presenting strategic opportunities for market share growth [6]

证券代码：000963 证券简称：华东医药 公告编号：2025-020 华东医药股份有限公司 注射用 DR30206 在中国的首个临床试验于 2023 年 6 月获得 NMPA 批准，适应症为晚期实体瘤（详见公司披露于巨潮资讯网的相 关公告，公告编号：2023-043）。 2025 年 1 月，道尔生物向 NMPA 递交了 DR30206 联合标准化疗 用于晚期或转移性消化道肿瘤患者的治疗的临床试验申请获得受理， 并于近日获得批准，同意本品开展临床试验。 三、对上市公司的影响及风险提示 截至目前，全球尚无同时靶向 PD-L1、VEGF 和 TGF-β 的抗体 融合蛋白药物上市，此次注射用 DR30206 联合标准化疗用于晚期或 转移性消化道肿瘤患者在中国的临床试验获批，是该款新药研发进程 中的又一大重要进展。 关于控股子公司获得药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 4 月 3 日，华东医药股份有限公司（以下简称"公司"） 控股子公司浙江道尔生物科技有限公司（以下简称"道尔生物"）收到 国家药品监督管理局（N ...

Suspension and Resumption of Trading - Tianyang New Materials' controlling shareholder is planning a change in control, leading to stock suspension [1] - Taihe Water's controlling shareholder and actual controller are planning a significant matter involving the transfer of part or all of the company's shares, resulting in stock suspension [1] - Hunan Development intends to purchase 90% equity of Tongwan Hydropower held by Xiangtou Energy, with stock resuming trading tomorrow [1] Private Placement - Huali Chuantong plans to raise no more than 450 million yuan through a private placement for projects related to radiation-resistant modules, multi-mode satellite communication SOC chips, and global multi-mode navigation systems [2] Share Transfer and Buyback - XGIMI Technology's shareholder intends to transfer 1.75 million shares, accounting for 2% of the total shares [3] - Zhongheng Group plans to repurchase shares worth between 300 million to 500 million yuan [4] External Investment and Daily Operations - Fengcai Technology intends to invest 28 million yuan to acquire 9.06% of Huake Zhixin [5] - Hongjing Technology signed a 312 million yuan contract for computing power services with China Mobile Ningxia [6] - Yaxiang Integration's Singapore branch plans to bid for a project worth approximately 3.163 billion yuan [7] - Shenglong Co., Ltd. received a notification for the development of flying cars, with an expected total sales amount of 120 million yuan over five years [8] - Huadong Medicine's wholly-owned subsidiary received acceptance notice for the marketing authorization application of Semaglutide injection [9] - Guyue Longshan has raised prices on some products [10] - Chengdi Xiangjiang's wholly-owned subsidiary received a formal contract for a data center project from China Telecom Shanghai, valued at 616 million yuan [10] - Deyue Co., Ltd. plans to invest no more than 2.127 billion yuan to build a production line with an annual capacity of 16 GWh [10] - Ankai Micro released a low-power intelligent vision chip [11] Performance Changes - Xianggang Technology expects a net profit increase of 713% to 917% year-on-year in Q1 2025, driven by significant revenue growth, improved operational efficiency, and cost control [12] - SAIC Group reported March sales of 125,700 new energy vehicles, a year-on-year increase of 48.22% [13]

Core Insights - Huadong Medicine's subsidiary, Jiangdong Company, received acceptance for the marketing application of Semaglutide injection for blood sugar control in adults with type 2 diabetes [1] - The clinical trial application for Semaglutide's weight management indication was approved in September 2024, with the Phase III trial completed in December 2024 [1] - Semaglutide is recognized for its significant market potential due to its effective blood sugar and weight management capabilities [2] Industry Overview - The global diabetes market is experiencing substantial growth, with the number of adults with diabetes increasing from approximately 200 million in 1990 to 828 million in 2022 [4] - In China, the number of adult diabetes patients reached about 148 million in 2022, accounting for 18% of the global total, with a high untreated rate of 52.7% [4] - The diabetes treatment market is expected to grow as clinical diagnosis and treatment rates improve [4] Company Developments - Huadong Medicine has a comprehensive pipeline of over 20 commercialized and in-development products targeting various diabetes treatment mechanisms, including GLP-1 receptor agonists [5] - The company’s Semaglutide injection demonstrated comparable efficacy and safety to Novo Nordisk's control drug in Phase III trials, with slightly lower adverse event rates [3] - Huadong Medicine is advancing multiple innovative products, including oral small molecule GLP-1 receptor agonists and dual-target agonists, with ongoing clinical trials [6][7] Market Position - Huadong Medicine is positioned as a strong competitor in the diabetes treatment sector, leveraging its extensive GLP-1 product pipeline and research capabilities [7] - The company aims to become a leading player in the GLP-1 market, capitalizing on its comprehensive product offerings and competitive advantages [7]

华东医药股份有限公司 关于全资子公司收到药品注册受理通知书的公告 证券代码：000963 证券简称：华东医药 公告编号：2025-019 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 3 月 31 日，华东医药股份有限公司（以下简称"公司"） 全资子公司杭州中美华东制药江东有限公司（以下简称"江东公司"） 收到国家药品监督管理局（NMPA）签发的《受理通知书》（受理号： CXSS2500040；CXSS2500041；CXSS2500042；CXSS2500043），由 江东公司申报的司美格鲁肽注射液（研发代码：HDG1901）上市许可 申请获得受理。现将有关详情公告如下： 一、该药物基本信息内容 药物名称：司美格鲁肽注射液 申请事项：境内生产药品注册上市许可 注册分类：治疗用生物制品 3.3 类 规格：1.34mg/ml，1.5ml（笔芯）；1.34mg/ml，1.5ml（预填充 注射笔）；1.34mg/ml，3ml（笔芯）；1.34mg/ml，3ml（预填充注射 笔） 申报适应症：本品适用于成人 2 型糖尿病患者的血糖控制。 申请人：杭州中 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000963 证券简称：华东医药 公告编号：2025-018 华东医药股份有限公司关于部分限制性股票回购注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 1、本次回购注销的限制性股票为华东医药股份有限公司2022年限制性股票激励计划已授予但尚未解除 限售的部分限制性股票；本次回购注销涉及18名激励对象，回购注销的限制性股票共计18.55万股，占 本次回购注销前公司总股本比例为0.01%； 2、本次限制性股票回购价格为23.78元/股，回购款项合计4,621,985.34元，含代扣代缴个人所得税以及 相应利息； 3、本次回购注销完成后，公司总股本由1,754,262,548.00股减少至1,754,077,048.00股； 4、截至本公告披露日，公司已在中国证券登记结算有限责任公司深圳分公司完成了上述限制性股票的 回购注销手续。 华东医药股份有限公司（以下简称"公司"）于2024年11月25日召开第十届董事会第三十次会议和第十届 监事会第二十次会议，并于2024年12月20日召 ...

证券代码：000963 证券简称：华东医药 公告编号：2025-018 华东医药股份有限公司 关于部分限制性股票回购注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次回购注销的限制性股票为华东医药股份有限公司2022年 限制性股票激励计划已授予但尚未解除限售的部分限制性股票；本次 回购注销涉及18名激励对象，回购注销的限制性股票共计18.55万股， 占本次回购注销前公司总股本比例为0.01%； 2、本次限制性股票回购价格为23.78元/股，回购款项合计 4,621,985.34元，含代扣代缴个人所得税以及相应利息； 3、本次回购注销完成后，公司总股本由1,754,262,548.00股减少 至1,754,077,048.00股； 4、截至本公告披露日，公司已在中国证券登记结算有限责任公 司深圳分公司完成了上述限制性股票的回购注销手续。 华东医药股份有限公司（以下简称"公司"）于2024年11月25日召 开第十届董事会第三十次会议和第十届监事会第二十次会议，并于 2024年12月20日召开2024年第二次临时股东大会，审议通过了 ...